HRP20150998T1 - Mimetici apolipoproteina a-i - Google Patents
Mimetici apolipoproteina a-i Download PDFInfo
- Publication number
- HRP20150998T1 HRP20150998T1 HRP20150998TT HRP20150998T HRP20150998T1 HR P20150998 T1 HRP20150998 T1 HR P20150998T1 HR P20150998T T HRP20150998T T HR P20150998TT HR P20150998 T HRP20150998 T HR P20150998T HR P20150998 T1 HRP20150998 T1 HR P20150998T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- pharmaceutically acceptable
- acceptable salt
- leu
- lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15296009P | 2009-02-16 | 2009-02-16 | |
| US15296609P | 2009-02-16 | 2009-02-16 | |
| US15296209P | 2009-02-16 | 2009-02-16 | |
| EP10741801.4A EP2396017B1 (en) | 2009-02-16 | 2010-02-12 | Apolipoprotein a-i mimics |
| PCT/US2010/024096 WO2010093918A1 (en) | 2009-02-16 | 2010-02-12 | Apolipoprotein a-i mimics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150998T1 true HRP20150998T1 (hr) | 2015-11-20 |
Family
ID=42562076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150998TT HRP20150998T1 (hr) | 2009-02-16 | 2010-02-12 | Mimetici apolipoproteina a-i |
| HRP20170294TT HRP20170294T1 (hr) | 2009-02-16 | 2017-02-22 | Mimetici apolipoproteina a-i |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170294TT HRP20170294T1 (hr) | 2009-02-16 | 2017-02-22 | Mimetici apolipoproteina a-i |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US8378068B2 (enExample) |
| EP (2) | EP2939683B1 (enExample) |
| JP (2) | JP5719783B2 (enExample) |
| KR (1) | KR101688547B1 (enExample) |
| CN (2) | CN102395375B (enExample) |
| AU (1) | AU2010213568B2 (enExample) |
| CA (2) | CA2982157A1 (enExample) |
| CY (1) | CY1118809T1 (enExample) |
| DK (2) | DK2396017T3 (enExample) |
| ES (2) | ES2620478T3 (enExample) |
| HK (1) | HK1209436A1 (enExample) |
| HR (2) | HRP20150998T1 (enExample) |
| HU (2) | HUE026062T2 (enExample) |
| IL (2) | IL214576B (enExample) |
| LT (1) | LT2939683T (enExample) |
| MX (3) | MX343654B (enExample) |
| NZ (1) | NZ594516A (enExample) |
| PH (1) | PH12016501912A1 (enExample) |
| PL (2) | PL2396017T3 (enExample) |
| PT (2) | PT2939683T (enExample) |
| RU (2) | RU2532222C2 (enExample) |
| SG (1) | SG173624A1 (enExample) |
| SI (2) | SI2939683T1 (enExample) |
| SM (2) | SMT201700203T1 (enExample) |
| WO (1) | WO2010093918A1 (enExample) |
| ZA (1) | ZA201105997B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8163699B2 (en) * | 2006-06-01 | 2012-04-24 | Montreal Heart Institute | Method for the treatment of valvular disease |
| US20120141576A1 (en) * | 2007-03-15 | 2012-06-07 | Benjamin Johnson | Treatment of Dermatologic Skin Disorders |
| WO2008141230A1 (en) | 2007-05-09 | 2008-11-20 | Lawrence Livermore National Security, Llc | Methods and systems for monitoring production of a target protein in a nanolipoprotein particle |
| US9688718B2 (en) | 2008-01-11 | 2017-06-27 | Lawrence Livermore National Security, Llc | Nanolipoprotein particles comprising hydrogenases and related products, methods and systems |
| DK2396017T3 (en) | 2009-02-16 | 2015-09-14 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-I-mimetika |
| ES2648788T3 (es) | 2011-01-26 | 2018-01-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Método para evaluar el riesgo de un sujeto de tener una enfermedad cardiovascular |
| HUE042314T2 (hu) | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
| AU2015271986B2 (en) * | 2011-02-07 | 2018-02-22 | Cerenis Therapeutics Holding Sa | Lipoprotein complexes and manufacturing and uses thereof |
| US9644038B2 (en) | 2011-12-21 | 2017-05-09 | The Regents Of The University Of California | Apolipoprotein nanodiscs with telodendrimer |
| WO2013188879A1 (en) | 2012-06-16 | 2013-12-19 | Atherotech, Inc. | Measurement of serum lipoproteins |
| US9239280B2 (en) * | 2012-06-16 | 2016-01-19 | Atherotech, Inc. | Measurement of serum lipoproteins |
| MX2016014306A (es) | 2014-05-02 | 2017-06-12 | Cerenis Therapeutics Holding Sa | Marcadores para terapia con lipoproteinas de alta densidad (hdl). |
| WO2016049061A1 (en) | 2014-09-22 | 2016-03-31 | Lawrence Livermore National Security, Llc | Electrochemical flow-cell for hydrogen production and nicotinamide co-factor dependent target reduction, and related methods and systems |
| EP3273944B1 (en) | 2015-03-25 | 2024-11-20 | The Regents of The University of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| WO2017035326A1 (en) | 2015-08-25 | 2017-03-02 | Lawrence Livermore National Security, Llc | Stable nanolipoprotein particles and related compositions methods and systems |
| WO2017044899A1 (en) * | 2015-09-11 | 2017-03-16 | Lawrence Livermore National Security, Llc | Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation |
| US20190201540A1 (en) * | 2016-05-24 | 2019-07-04 | Stc Unm | Immunogens, compositions, and methods for treating dyslipidemia |
| US12083223B2 (en) | 2017-05-02 | 2024-09-10 | Lawrence Livermore National Security, Llc | Nanolipoprotein particles and related compositions methods and systems for loading RNA |
| WO2018204421A2 (en) | 2017-05-02 | 2018-11-08 | Lawrence Livermore National Security, Llc | Momp telonanoparticles, and related compositions, methods and systems |
| TW201919686A (zh) * | 2017-08-10 | 2019-06-01 | 法商塞勒尼斯醫療控股公司 | 脫輔基子(apomers) |
| WO2019030574A1 (en) * | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding | Cargomers |
| WO2021209808A1 (en) * | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Cer-001 therapy for treating kidney disease |
| CN115666720A (zh) | 2020-04-16 | 2023-01-31 | 阿比奥尼克斯制药公司 | 用于治疗肾病的cer-001疗法 |
| EP4135747A1 (en) | 2020-04-16 | 2023-02-22 | Abionyx Pharma SA | Methods for treating acute conditions using lipid binding protein- based complexes |
| JP2023543498A (ja) | 2020-10-01 | 2023-10-16 | アビオニクス ファーマ エスエー | 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法 |
| EP4259280A4 (en) * | 2020-12-11 | 2025-02-12 | The Regents Of The University Of Michigan | Compositions and methods for preventing, attenuating, and treating medical conditions with shdl nanoparticles |
| JP2024514154A (ja) | 2021-04-15 | 2024-03-28 | アビオニクス ファーマ エスエー | 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用 |
| CN114940711B (zh) * | 2021-10-25 | 2023-05-12 | 中山大学 | 载脂蛋白a-i模拟肽及其应用 |
| EP4504150A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating eye diseases using lipid binding protein-based complexes |
| EP4504233A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
| CN120344255A (zh) | 2022-06-10 | 2025-07-18 | 阿比奥尼克斯制药公司 | 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法 |
| EP4536269A2 (en) | 2022-06-10 | 2025-04-16 | Abionyx Pharma SA | Methods for treating acute conditions using lipid binding protein-based complexes |
| US12060148B2 (en) | 2022-08-16 | 2024-08-13 | Honeywell International Inc. | Ground resonance detection and warning system and method |
| AU2024207875A1 (en) | 2023-01-13 | 2025-07-24 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH621479A5 (enExample) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
| CA1173360A (en) * | 1979-06-22 | 1984-08-28 | Jurg Schrank | Pharmaceutical preparations |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4643988A (en) * | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| JPS61152632A (ja) | 1984-12-26 | 1986-07-11 | Dai Ichi Seiyaku Co Ltd | 抗動脈硬化剤 |
| US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5972890A (en) * | 1988-05-02 | 1999-10-26 | New England Deaconess Hospital Corporation | Synthetic peptides for arterial imaging |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| JPH0559081A (ja) | 1991-08-29 | 1993-03-09 | Kirin Brewery Co Ltd | 新規スフインゴ糖脂質、その製造法および使用 |
| WO1993025581A1 (en) | 1992-06-12 | 1993-12-23 | N.V. Innogenetics S.A. | New peptides and proteins, process for their preparation and their use as cholesterol acceptors |
| TW261533B (enExample) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| US5674855A (en) | 1992-08-12 | 1997-10-07 | The Rogosin Institute | Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions |
| CA2143848C (en) | 1992-10-01 | 2007-09-11 | W. Clark Still | Complex combinatorial chemical libraries encoded with tags |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| FR2734568B1 (fr) | 1995-05-22 | 1997-06-20 | Rhone Poulenc Rorer Sa | Nouveaux variants de l'apolipoproteine |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6518412B1 (en) * | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| AU765809B2 (en) | 1998-02-12 | 2003-10-02 | Emory University | Sphingolipid derivatives and their methods of use |
| CN1329359C (zh) | 1999-04-01 | 2007-08-01 | 埃斯佩里安医疗公司 | 醚化合物,及其组合物和用途 |
| PT1290013E (pt) * | 2000-04-21 | 2006-06-30 | Amgen Inc | Derivados dos peptidos apo-ai/aii |
| US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7144862B2 (en) * | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| CA2460787A1 (en) | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Prevention and treatment of restenosis by local administration of drug |
| BR0310099A (pt) * | 2002-05-17 | 2007-03-20 | Esperion Therapeutics Inc | método para tratar dislipidemia ou uma doença associada com a dislipidemia |
| DE10237571A1 (de) | 2002-08-13 | 2004-02-26 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | Endovaskuläres Implantat mit aktiver Beschichtung |
| AU2004252174A1 (en) | 2003-06-26 | 2005-01-06 | Migenix Inc. | Compositions of lipopeptide antibiotic derivatives and methods of use thereof |
| BRPI0513402A (pt) * | 2004-07-16 | 2008-05-06 | Tufts College | miméticos de apolipoproteìna a1 e usos dos mesmos |
| US8206750B2 (en) * | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| JP2008542685A (ja) | 2005-05-05 | 2008-11-27 | ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット | サイトカイン受容体修飾因子及びその使用 |
| TW200744627A (en) | 2006-02-21 | 2007-12-16 | Pfizer Prod Inc | Methods for the treatment of macular degeneration and related eye conditions |
| US8163699B2 (en) * | 2006-06-01 | 2012-04-24 | Montreal Heart Institute | Method for the treatment of valvular disease |
| US20080138284A1 (en) * | 2006-09-26 | 2008-06-12 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
| WO2008094905A2 (en) | 2007-01-29 | 2008-08-07 | Lipid Sciences, Inc. | Encapsulated hdl mimetic peptides |
| US7956035B2 (en) | 2007-03-01 | 2011-06-07 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
| AU2008266753A1 (en) | 2007-06-20 | 2008-12-24 | Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. | ApoA-1 peptide mimetics |
| US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| WO2010083611A1 (en) | 2009-01-23 | 2010-07-29 | Institut De Cardiologie De Montreal | Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex |
| DK2396017T3 (en) | 2009-02-16 | 2015-09-14 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-I-mimetika |
| US20130197226A1 (en) * | 2010-07-28 | 2013-08-01 | Jean-Claude Tardif | Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex |
| CN105051051B (zh) | 2013-03-15 | 2021-07-16 | 萨瑞斯治疗控股公司 | 用于合成神经鞘磷脂和二氢神经鞘磷脂的方法 |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
-
2010
- 2010-02-12 DK DK10741801.4T patent/DK2396017T3/en active
- 2010-02-12 HR HRP20150998TT patent/HRP20150998T1/hr unknown
- 2010-02-12 SG SG2011057569A patent/SG173624A1/en unknown
- 2010-02-12 NZ NZ594516A patent/NZ594516A/xx not_active IP Right Cessation
- 2010-02-12 EP EP15157397.9A patent/EP2939683B1/en active Active
- 2010-02-12 ES ES15157397.9T patent/ES2620478T3/es active Active
- 2010-02-12 AU AU2010213568A patent/AU2010213568B2/en active Active
- 2010-02-12 MX MX2014006888A patent/MX343654B/es unknown
- 2010-02-12 PL PL10741801T patent/PL2396017T3/pl unknown
- 2010-02-12 SM SM20170203T patent/SMT201700203T1/it unknown
- 2010-02-12 DK DK15157397.9T patent/DK2939683T3/en active
- 2010-02-12 PT PT151573979T patent/PT2939683T/pt unknown
- 2010-02-12 MX MX2011008599A patent/MX2011008599A/es active IP Right Grant
- 2010-02-12 ES ES10741801.4T patent/ES2554853T3/es active Active
- 2010-02-12 US US12/705,094 patent/US8378068B2/en active Active
- 2010-02-12 WO PCT/US2010/024096 patent/WO2010093918A1/en not_active Ceased
- 2010-02-12 LT LTEP15157397.9T patent/LT2939683T/lt unknown
- 2010-02-12 RU RU2011138011/10A patent/RU2532222C2/ru not_active IP Right Cessation
- 2010-02-12 SI SI201031428A patent/SI2939683T1/sl unknown
- 2010-02-12 CA CA2982157A patent/CA2982157A1/en not_active Abandoned
- 2010-02-12 PT PT107418014T patent/PT2396017E/pt unknown
- 2010-02-12 PL PL15157397T patent/PL2939683T3/pl unknown
- 2010-02-12 CN CN201080016764.XA patent/CN102395375B/zh active Active
- 2010-02-12 EP EP10741801.4A patent/EP2396017B1/en active Active
- 2010-02-12 HU HUE10741801A patent/HUE026062T2/en unknown
- 2010-02-12 CA CA2752182A patent/CA2752182C/en active Active
- 2010-02-12 HU HUE15157397A patent/HUE033661T2/en unknown
- 2010-02-12 CN CN201410745103.0A patent/CN104530223A/zh active Pending
- 2010-02-12 SI SI201031020T patent/SI2396017T1/sl unknown
- 2010-02-12 KR KR1020117021736A patent/KR101688547B1/ko not_active Expired - Fee Related
- 2010-02-12 MX MX2016014789A patent/MX386110B/es unknown
- 2010-02-12 JP JP2011550271A patent/JP5719783B2/ja active Active
-
2011
- 2011-08-10 IL IL214576A patent/IL214576B/en active IP Right Grant
- 2011-08-16 ZA ZA2011/05997A patent/ZA201105997B/en unknown
-
2013
- 2013-02-13 US US13/766,561 patent/US8993597B2/en active Active
-
2014
- 2014-08-21 RU RU2014134333A patent/RU2014134333A/ru not_active Application Discontinuation
-
2015
- 2015-02-05 US US14/614,771 patent/US9388232B2/en active Active
- 2015-03-23 JP JP2015058887A patent/JP2015110677A/ja active Pending
- 2015-08-04 IL IL240357A patent/IL240357A/en not_active IP Right Cessation
- 2015-10-16 HK HK15110156.2A patent/HK1209436A1/xx unknown
- 2015-12-18 SM SM201500318T patent/SMT201500318B/it unknown
-
2016
- 2016-07-11 US US15/207,158 patent/US9981008B2/en active Active
- 2016-09-27 PH PH12016501912A patent/PH12016501912A1/en unknown
-
2017
- 2017-02-22 HR HRP20170294TT patent/HRP20170294T1/hr unknown
- 2017-03-27 CY CY20171100374T patent/CY1118809T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150998T1 (hr) | Mimetici apolipoproteina a-i | |
| Liu et al. | Targeted liposomal drug delivery: a nanoscience and biophysical perspective | |
| JP2012518006A5 (enExample) | ||
| ES2819059T3 (es) | Liposomas que encapsulan conjuntamente un bifosfonato y un agente anfipático | |
| Sandström et al. | Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes | |
| WO2008109031A3 (en) | Liposome carriers for in vivo delivery of fullerenes | |
| Koynova et al. | Cationic phospholipids: structure–transfection activity relationships | |
| RU2000111523A (ru) | Образование пептид/липидного комплекса путем совместной лиофилизации | |
| EP2440250A1 (en) | Targeted liposomes comprising n-containing bisphosphonates and uses thereof | |
| JP2015502400A5 (enExample) | ||
| Patel et al. | Liposome drug delivery system: a critic review | |
| Prince et al. | Attenuation of neuroblastoma cell growth by nisin is mediated by modulation of phase behavior and enhanced cell membrane fluidity | |
| Orthmann et al. | Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes | |
| US20190224124A1 (en) | Methods and Kits for Reducing the Susceptibility of Lipoprotein Particles to Atherogenic Aggregation Induced by Arterial-Wall Enzymes | |
| WO2008051818A8 (en) | Spontaneously forming ellipsoidal phospholipid unilamellar vesicles | |
| Maheswaran et al. | Liposomal drug delivery systems—a review | |
| JP2008519064A5 (enExample) | ||
| Efimova et al. | Effect of cholesterol on the phase state and permeability of mixed liposomes composed of anionic diphosphatidylglycerol and zwitterionic dipalmitoylphosphatidylcholine | |
| Neves et al. | Characterization of membrane protein reconstitution in LUVs of different lipid composition by fluorescence anisotropy | |
| de Kruijff et al. | Effects of an integral membrane glycoprotein on phospholipid vesicle fusion | |
| EP2398463A1 (en) | A method for amphiphilic drug loading in liposomes by ion gradient | |
| Veerapu et al. | Review on novel carrier system: liposomes and proliposomes | |
| AR059591A1 (es) | Metodos para el tratamiento de la degeneracion macular y afecciones oculares relacionadas | |
| FI3954360T3 (fi) | Hiilihydraattien lääkevalmiste terapeuttiseen käyttöön | |
| KR100996975B1 (ko) | 혈류 내 순환시간 증가를 위한 단백질로 수식된 리포솜 및이의 제조방법 |